Project Grant RF1AG077475
Award Date
6/1/22
Completion Date
5/31/25
Dollars Obligated
$1.3M
Federal Agency
National Institute on Aging
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
East Lansing, MI 48824, USA
Similar Awards
The National Institute on Aging (NIA) awarded a $773,816 Project Grant (CFDA 93.866 - Aging Research) to the University of California, Irvine to conduct a comprehensive study on the molecular mechanisms underlying aberrant protein accumulation in Alzheimer's disease-related tauopathies. The project aims to generate cell-type-specific atlases of misprocessed RNAs and proteins in mouse models and human brain tissues to identify new pathways and protein interaction networks involved in...
The National Institute on Aging (NIA) awarded a $1,709,482 Project Grant (CFDA 93.866 - Aging Research) to the Seattle Institute for Biomedical and Clinical Research to investigate how the SUT-6/NIPP1 protein regulates pathological tau in Alzheimer's disease and other neurodegenerative "tauopathies". The 5-year grant, running from Aug 1, 2024 to Apr 30, 2029, aims to: 1) define the functions of SUT-6/NIPP1 important for suppressing tau toxicity; 2) determine downstream mediators of...
The National Institute on Aging (NIA) awarded a $7,249,563 Project Grant under the Aging Research federal grant program (CFDA 93.866) to the Regents of the University of California, San Francisco (UCSF). This 3-year award, starting on Aug 1, 2023, will support research to characterize the structural properties and variability of tau protein aggregation in different brain cell types and at different disease stages of Alzheimer's and related dementias (ADRD). The project aims to develop new...
This federal Project Grant award of $1,118,700.00 from the National Institute on Aging (CFDA 93.866 - Aging Research) to New York University School of Medicine will support research to elucidate the role of pathological tau protein in disrupting endosomal microautophagy (EMI), a critical protein degradation pathway affected in Alzheimer's disease. The research aims to determine which components of the EMI pathway are most vulnerable to tau pathology and whether restoring EMI function can...
This National Institute on Aging R01 Project Grant Award (CFDA 93.866 - Aging Research) provides $745,092 to the University of Virginia to conduct research on the epitranscriptomic mechanisms underlying the pathogenesis of Alzheimer's disease (AD) and related tauopathies. The key objectives are to: 1) Decode the epitranscriptomic profiles impacted by tau pathology using m6A DART-seq, 2) Determine the role of RNA methylation in AD pathogenesis using 3D neuron-glial brain assembloids, and 3)...
This $1,592,854 project grant was awarded by the National Institute on Aging (CFDA 93.866 - Aging Research) to the University of Illinois to investigate the molecular mechanisms underlying tau protein dysfunction in neurodegenerative tauopathies, including Alzheimer's disease and related dementias. The overarching goal is to understand how disease-related changes in tau conformation and post-translational modifications disrupt tau's normal scaffolding functions and lead to dysregulation of key...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports research into the role of local protein synthesis in the development of tau pathology and neurodegeneration associated with Alzheimer's disease. The $1,147,300 grant awarded to Wayne State University will fund a 5-year project to investigate how pathogenic forms of the tau protein interfere with dendritic protein synthesis, which may contribute to the early synaptic dysfunction seen in...
This federal Project Grant award of $816,661 from the National Institute on Aging (CFDA 93.866 - Aging Research) supports a research initiative by the Regents of the University of California, San Francisco (UCSF) to comprehensively map the impact of tau pathology on the proteome, which is expected to be mediated in part through disruptions in mRNA splicing. The research leverages AD mouse models and human iPSC tauopathy models to discover protein drivers of tauopathy and validate such drivers in...
This $1,823,353 Project Grant awarded by the National Institute on Aging (CFDA 93.866 Aging Research) to the Seattle Institute For Biomedical And Clinical Research aims to elucidate the molecular mechanisms by which pathological tau protein causes neurodegeneration in Alzheimer's disease (AD) and related tauopathy disorders. The research project will leverage a C. elegans model of tauopathy to investigate the functional role of nuclear speckles, membraneless organelles involved in RNA...
This Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) provides $2,181,250 in funding to the Seattle Institute For Biomedical And Clinical Research to develop small molecule inhibitors of the MSUT2 protein as a potential therapeutic approach for treating tauopathy disorders such as frontotemporal lobar degeneration, Alzheimer's disease, and related conditions. The project aims to optimize potent and brain-penetrant MSUT2 inhibitors and demonstrate...